SCIENCEDOMAIN *international*
www.sciencedomain.org

SDI Review Form 1.6

Journal Name:	Asian Journal of Applied Chemistry Research
Manuscript Number:	**Ms_AJACR_50912**
Title of the Manuscript:	**Validated Stability – Indicating Methods for Determination of Sofosbuvir by UPLC and HPTLC in Pure Form and Tablet Dosage forms.**
Type of the Article	**Original Research Article**

General guideline for Peer Review process:

This journal's peer review policy states that **NO** manuscript should be rejected only on the basis of '**lack of Novelty'**, provided the manuscript is scientifically robust and technically sound.
To know the complete guideline for Peer Review process, reviewers are requested to visit this link:

(http://www.sciencedomain.org/page.php?id=sdi-general-editorial-policy#Peer-Review-Guideline)

SDI Review Form 1.6

PART 1: Review Comments

<table>
<tr><th></th><th>Reviewer's comment</th><th>Author's comment (if agreed with reviewer, correct the manuscript and highlight that part in the manuscript. It is mandatory that authors should write his/her feedback here)</th></tr>
<tr><td><u>Compulsory</u> REVISION comments</td><td>
Copy of Revision cited are attached to this document
Needed

<u>Compulsory Revision Comments</u>
<table>
<tr><th>Page number</th><th>Line number</th><th>Revisions raised</th><th>Revisions corrected</th></tr>
<tr><td>2</td><td>19,20,21</td><td>against HCV. The HCV polymerase (NS5B protein) is an RNA-dependent RNA polymerase (RdRp). It is the essential initiating and catalytic subunit of this replication complex and is critical for the viral replication cycle (2).</td><td>for the treatment of adult patients with chronic <u>hepatitis C virus</u> (HCV) infection. It interferes with the HCV lifecycle, restraining viral replication.</td></tr>
<tr><td>3</td><td>51</td><td>of 5N NaOH for 3.5 h</td><td>of 5N NaOH for 3 h</td></tr>
<tr><td>3</td><td>59,60</td><td>into 100- mL volumetric flask</td><td>into 100 mL volumetric flask</td></tr>
<tr><td>3</td><td>61</td><td>claimed to contain degradates derived from 0.1mg mL^{-1} intact drug which was used for the</td><td>claimed to contain degradates derived from 0.1mg mL^{-1} of intact drug, which was used for the</td></tr>
<tr><td></td><td>72</td><td>obtain working standard solution of 0.1mg mL^{-1}.</td><td>obtain working standard solution of concentration 0.1mg mL^{-1}.</td></tr>
<tr><td>4</td><td>77,78</td><td>Kinetex 2.6µ C_{18} 100A (4.6-mm × 100-mm)</td><td>Kinetex 2.6µ C_{18} column 100A (4.6-mm × 100-mm)</td></tr>
<tr><td>4</td><td>80,81</td><td>at flow rate 1 mL $min^{-1,}$ the injection volume was 10 µL and the detection at 260 nm.</td><td>at a flow rate 1.0 mL min^{-1} with an injection volume of 10 µL and the detection at 260 nm.</td></tr>
<tr><td>4</td><td>95</td><td>Triplicate 10 µL of each solution were injected into the UPLC system and chromatographed</td><td>10 µL of each solution were injected into the UPLC system in triplicate and chromatographed</td></tr>
<tr><td>4</td><td></td><td>Different aliquots of of intact sofosbuvir working standard solution (0.1mg mL^{-1})</td><td>Different aliquots of intact sofosbuvir working standard solution (0.1mg mL^{-1})</td></tr>
<tr><td>5</td><td>113</td><td>Different aliquots of stock drug solution (1 mg mL^{-1}) containing (1–11 mg)</td><td>Different aliquots of stock drug solution (1 mg mL^{-1}) containing (1.0–11 mg)</td></tr>
<tr><td>5</td><td>130</td><td>sofosbuvir in presence of its degradation product by UPLC and HPTLC methods</td><td>sofosbuvir in presence of its degradation products by UPLC and HPTLC methods</td></tr>
<tr><td>6</td><td>176</td><td>- conc. ammonia (2.5: 6: 1.5 v/v/v).</td><td>- conc. ammonia(2.5: 6: 1.5 %v/v/v).</td></tr>
<tr><td>13</td><td>278</td><td>*Avarage</td><td>*Average</td></tr>
<tr><td>16</td><td>324</td><td>1. <u>https://www.drugbank.ca/drugs/DB08934</u>.</td><td><u>https://www.drugbank.ca/drugs/DB08934.</u></td></tr>
</table>
</td><td></td></tr>
<tr><td><u>Minor</u> REVISION comments</td><td></td><td></td></tr>
</table>

SDI Review Form 1.6

Optional/General comments		

PART 2:

	Reviewer's comment	**Author's comment** *(if agreed with reviewer, correct the manuscript and highlight that part in the manuscript. It is mandatory that authors should write his/her feedback here)*
Are there ethical issues in this manuscript?	*(If yes, Kindly please write down the ethical issues here in details)*	

Reviewer Details:

Name:	***D. Ramachandran***
Department, University & Country	***Acharya Nagarjuna University, India***